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Abstract
Background  and  objective: Previous  studies  regarding  the  effects  of  some  local  anaesthetics
have suggested  that  these  agents  can  cause  genetic  damage.  However,  they  have  not  been
tested  for  genotoxicity  related  to  repetitive  administration.  The  aim  of  this  study  was  to
evaluate  the  genotoxic  potential  of  local  anaesthetics  upon  repetitive  administration.
Methods: 80  male  Wistar  rats  were  divided  into:  group  A  --  16  rats  intraperitoneally  injected
with lidocaine  hydrochloride  2%;  group  B  --  16  rats  IP  injected  with  mepivacaine  2%;  group  C  --  16
rats  intraperitoneally  injected  with  articaine  4%;  group  D  --  16  rats  IP  injected  with  prilocaine  3%
(6.0  mg/kg);  group  E  --  8  rats  subcutaneously  injected  with  a  single  dose  of  cyclophosphamide;
and group  F  --  8  rats  intraperitoneally  injected  with  saline.  Eight  rats  from  groups  A  to  D  received
a  single  dose  of  anaesthetic  on  Day  1  of  the  experiment;  the  remaining  rats  were  dosed  once  a
day  for  5  days.
Results:  The  median  number  of  micronuclei  in  the  local  anaesthetics  groups  exposed  for  1  or
5  days  ranged  from  0.00  to  1.00,  in  the  cyclophosphamide-exposed  group  was  10.00,  and  the
negative  control  group  for  1  and  5  days  was  1.00  and  0.00,  respectively  (p  <  0.0001).  A  signiﬁcant
difference  in  the  number  of  micronuclei  was  observed  between  the  cyclophosphamide  group
and  all  local  anaesthetic  groups  (p  =  0.0001),  but  not  between  the  negative  control  group  and
the  local  anaesthetic  groups  (p  >  0.05).
Conclusion:  No  genotoxicity  effect  was  observed  upon  repetitive  exposure  to  any  of  the  local
anaesthetics evaluated.
© 2013  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  
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Avaliac¸ão  da  genotoxicidade  induzida  pela  administrac¸ão  repetida  de  anestésicos
locais:  um  estudo  experimental  em  ratos
Resumo
Justiﬁcativa  e  objetivos:  Estudos  anteriores  sobre  os  efeitos  de  alguns  anestésicos  locais  sug-
eriram que  esses  agentes  podem  causar  alterac¸ões  genéticas.  No  entanto,  esses  agentes  não  são
testados  para  genotoxicidade  relacionada  à  administrac¸ão  repetida.  O  objetivo  deste  estudo
foi  avaliar  o  potencial  genotóxico  de  anestésicos  locais  após  repetidas  administrac¸ões.
Métodos: 80  ratos  Wistar  machos  foram  alocados  em:  grupo  A  --  16  ratos  receberam  injec¸ão  por
via intraperitoneal  (IP)  de  cloridrato  de  lidocaína  a  2%;  grupo  B  --  16  ratos  receberam  injec¸ão
IP com  mepivacaína  a  2%;  grupo  C  -- 16 ratos  receberam  injec¸ão  IP  de  articaína  a  4%;  grupo  D
--  16  ratos  receberam  injec¸ão  IP  de  prilocaína  a  3%  (6,0  mg  kg−1);  grupo  E  --  8  ratos  receberam
injec¸ão subcutânea  em  dose  única  de  ciclofosfamida;  grupo  F  --  8  ratos  receberam  injec¸ão  IP
com  soluc¸ão  salina.  Oito  ratos  dos  grupos  de  A  a  D  receberam  uma  dose  única  de  anestésico  no
Dia  1  da  experiência;  os  ratos  restantes  foram  dosados  uma  vez  por  dia  durante  cinco  dias.
Resultados:  A  mediana  do  número  de  micronúcleos  nos  grupos  com  anestésicos  locais  expostos
por um  ou  cinco  dias  variou  de  0,00  a  1,00;  no  grupo  exposto  à  ciclofosfamida  foi  de  10,00
e  no  grupo  controle  negativo  no  primeiro  e  quinto  dias  foi  de  1,00  e  0,00,  respectivamente
(p <  0,0001).  Uma  diferenc¸a signiﬁcativa  foi  observada  no  número  de  micronúcleos  entre  o  grupo
ciclofosfamida  e  todos  os  grupos  com  anestésicos  locais  (p  =  0,0001),  mas  não  entre  o  grupo
controle  negativo  e  os  grupos  com  anestésicos  locais  (p  >  0,05).
Conclusão: Nenhum  efeito  de  genotoxicidade  foi  observado  após  a  exposic¸ão  repetida  a  qual-
quer um  dos  anestésicos  locais  avaliados.
©  2013  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  
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he  development  of  safe  and  effective  local  anaesthetic
gents has  been  one  of  the  most  important  advances  in  den-
al science  over  the  last  century.  The  dental  agents  currently
vailable are  extremely  safe  and  meet  most  of  the  crite-
ia for  an  ideal  local  anaesthetic.  These  local  anaesthetic
gents induce  minimal  tissue  irritation  and  have  a  low  risk
f inducing  allergic  reactions.1
A  local  anaesthetic  is  most  often  used  in  dentistry  to  con-
rol pain  and  is  also  widely  used  in  other  ﬁelds  of  medicine.
mong the  various  formulations  of  local  anaesthetics,  the
ost commonly  used  types  are  anaesthetic  salts  of  lido-
aine, mepivacaine  and  prilocaine.2
The  combined  use  of  a  vasoconstrictor  and  a  local
naesthetic agent  was  ﬁrst  reported  in  1901,  when  Braun
imultaneously administered  adrenaline  and  cocaine.3 Due
o the  vasodilation  properties  of  most  anaesthetic  salts,
he duration  of  anaesthesia  is  not  always  suitable,  illus-
rating the  necessity  of  concomitant  administration  with  a
asoconstrictor. Some  advantages  of  the  combined  admin-
stration of  vasoconstrictors  and  anaesthetics  are  the
low absorption  of  the  anaesthetic  salt  (which  reduces
oxicity and  increases  the  duration  of  anaesthesia),  a
eduction in  the  quantity  of  anaesthetic  required  to  anes-
hetise the  patient  and  an  increase  in  the  effectiveness
f the  anaesthetic.2 The  most  common  vasoconstrictors
sed in  combination  with  local  anaesthetics  belong  to
he group  of  sympathomimetic  amines,  which  includes
drenaline, noradrenaline,  levonordefrin,  phenylephrine
nd felypressin.2
Genotoxic  agents  negatively  affect  the  integrity  of  a
ell’s genetic  material  and  are  deﬁned  as  any  substance
e
p
mr  chemical  that  damages  DNA.  Although  the  ability  of
 substance  to  damage  DNA  does  not  automatically  ren-
er it  as  a  health  hazard,  it  does  raise  concerns  that
he substance  may  be  a  potential  mutagen  and/or  carci-
ogen.4
Some  local  anaesthetics  have  not  been  tested  for  carcino-
enicity or  genotoxicity.  Prilocaine  is  a  local  anaesthetic  that
as been  under  review  by  the  National  Toxicology  Program
NTP, USA)  since  October  2007.5
The  micronucleus  test  is  widely  used  to  evaluate  the  abil-
ty of  a  substance  to  break  chromosomes  (referred  to  as
ts clastogenicity)  or  affect  the  formation  of  the  mitotic
etaphase plate  and/or  spindle,  both  of  which  can  lead
o inequitable  distribution  of  chromosomes  during  cellu-
ar division.6 The  micronucleus  test  generates  results  with
trong statistical  support;  therefore,  it  is  widely  used  as  a
creening tool  to  determine  the  safety  of  many  substances
nd to  classify  agents  as  carcinogenic  or  non-carcinogenic.7
he  ease  of  implementation  of  the  micronucleus  test  has  led
o widespread  adoption  worldwide  as  a  standard  genotoxic-
ty test  to  monitor  the  safety  of  agents  for  use  in  the  human
opulation.8
To  the  best  of  our  knowledge,  there  are  no  studies  in  the
iterature addressing  the  genotoxic  potential  of  the  repeti-
ive use  of  local  anaesthetics.  Local  anaesthetics  are  widely
sed in  dentistry  and  medicine,  and  studies  that  evaluate
he risk  of  repetitive  exposure  to  these  substances  may
ontribute to  a  better  understanding  of  their  potentially
oxic effects  on  genetic  material  and  their  potential  risk  to
xposed patients.
The  objective  of  this  study  is  to  investigate  the  genotoxic
Este é um artigo Open Access sob a licença de CC BY-NC-NDotential of  the  repetitive  use  of  local  anaesthetics  using  the
icronucleus test.
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control group  and  the  local  anaesthetic  groups,  regardless  of
the type  of  anaesthetic  administered  or  the  time  of  exposure
(p >  0.05)  (Table  1).
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Figure  1  Micronuclei  counts  per  study  group  (median  and
interquartile intervals).  LIDO,  lidocaine;  MEPI,  mepivacaine;
ARTI, articaine;  PRILO,  prilocaine;  CONTROL,  negative  control;Genotoxicity  and  local  anaesthetics  
Methods
This  study  was  approved  by  the  Ethics  Committee  on  Animal
Use (Protocol  n◦ 930/11).
For this  study,  80  male  Wistar  rats  weighing  between
200 and  250  g  were  administered  local  anaesthetics
at 12  weeks  of  age.  The  rats  were  divided  into
groups of  four  in  large  rectangular  boxes  (measuring
49 cm  ×  34  cm  ×  16  cm)  suitable  for  the  accommodation  of
up to  ﬁve  adult  rats.  The  rats  were  placed  in  a  temperature-
and humidity-controlled  vivarium  equipped  with  a  12-h
light/dark cycle  light.  All  animals  were  weighed  prior
to anaesthetic  administration  to  calculate  the  proper
dosage.
The animals  were  divided  into  6  groups:  group  A
-- 16  rats  intraperitoneally  (IP)  injected  with  lidocaine
hydrochloride and  phenylephrine  (Novocol® 100,  SS  White,
Rio de  Janeiro,  Brazil)  at  a  dose  of  4.4  mg/kg,  group
B --  16  rats  IP  injected  with  mepivacaine  2%  (mepiva-
caine, DFL,  Jacarepaguá,  Brazil)  at  a  dose  of  4.4  mg/kg,
group C  --  16  rats  IP  injected  with  epinephrine  and
articaine 4%  (Septanest® 1:100,000,  Septodont,  Brussels,
Belgium) at  a  dose  of  7.0  mg/kg,  group  D  --  16  rats  IP
injected with  prilocaine  3%  and  felypressin  (Cytanest®,
Astra, Sao  Paulo,  Brazil)  at  a  dose  of  6.0  mg/kg,  group
E --  8  rats  subcutaneously  injected  with  a  single  dose
of cyclophosphamide  (Genuxal®,  Baxter  Oncology  GmbH,
Halle/Westfalen, Germany)  (50  mg/kg)  on  Day  1  of  the
experiment (positive  control  group),8 and  group  F  --  eight
mice IP  injected  with  0.5  mL  of  saline  (negative  control
group). Because  a  previous  report  demonstrated  the  forma-
tion of  micronuclei  in  response  to  cyclophosphamide  at  a
dose of  50  mg/kg,  this  dose  was  used  for  the  positive  control
group.8
Eight  rats  from  groups  A  to  D  received  one  dose  of  anaes-
thetic on  Day  1  of  the  experiment.  The  remaining  animals
in these  groups  received  a  daily  dose  of  anaesthetic  for
ﬁve days.  The  rats  in  group  F  were  administered  saline  in
a similar  manner.
Eight rats  from  groups  A  to  D,  four  rats  from  group  F,
and all  of  the  rats  in  group  E  were  euthanised  24  h after
administration of  the  anaesthetic.  The  remaining  animals
of groups  A,  B,  C,  D  and  F  were  euthanised  5  days  later.
Euthanasia was  performed  with  sodium  pentobarbital  (Syn-
tec, Cotia,  São  Paulo,  Brazil)  at  a  dose  of  100  mg/kg  by  IP
injection.
Bone marrow  samples  were  collected  from  the  femur  of
each rat  at  the  time  of  sacriﬁce,  and  two  sample  slides
were prepared  per  animal.8 The  slides  were  stained  with
Giemsa stain  (Dolles,  São  Paulo,  Brazil).  Two  thousand  poly-
chromatic erythrocytes  (1000  per  slide)  were  counted  for
each animal  at  a  magniﬁcation  of  400×  using  an  opti-
cal microscope  to  determine  the  number  of  micronuclei.8
Micronuclei  were  deﬁned  as  structures  with  probable  halos
surrounding the  nuclear  membrane  and  a  volume  of  less
than one-third  that  of  the  diameter  of  the  associated  nuclei;
the micronuclei  staining  intensity  was  similar  to  the  inten-
sity of  the  associated  nuclei,  and  both  structures  were
observed in  the  same  focal  plane.9 The  slide  analysis  was
performed in  a  blinded  manner  by  a  single  person  (MCO)
and reviewed  by  a  second  person  (GAN);  both  results  were
concordant.
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tatistical analysis
he  variance  in  micronuclei  frequency  did  not  have  a  normal
istribution when  analysed  by  the  Kolmogorov--Smirnov  test
p =  0.0001)  nor  were  the  variances  homogenous  (p  =  0.004)
y Levene  test  analysis.  We  therefore  chose  to  use  the
onparametric Kruskal--Wallis  test  followed  by  multiple
omparisons with  the  Student--Newman--Keuls  test  to  deter-
ine statistical  signiﬁcance.  All  statistical  tests  were
erformed at  a signiﬁcance  level  of  5%.
esults
he  median  number  of  micronuclei  observed  for  each  group
as as  follows:  for  the  lidocaine  group,  the  1-  and  5-day
xposures were  1.00  and  0.50,  respectively;  for  the  mepiva-
aine group,  the  1-  and  5-day  exposures  were  both  1.00;  for
he articaine  group,  the  1-  and  5-day  exposures  were  1.00
nd 0.00,  respectively;  and  for  the  prilocaine  group,  the  1-
nd 5-day  exposures  were  both  0.00.  In  the  group  exposed  to
yclophosphamide (the  positive  control),  the  median  num-
er of  micronuclei  was  10.00.  The  negative  control  groups
or days  1  and  5  had  median  numbers  of  micronuclei  of
.00 and  0.00,  respectively  (p  <  0.0001)  (Figs.  1  and  2  and
able 1).
The number  of  micronuclei  in  the  positive  control
roup (cyclophosphamide)  signiﬁcantly  differed  from  those
bserved for  all  of  the  local  anaesthetics  studied,  both  in
he type  of  anaesthetic  administered  and  the  time  of  expo-
ure (p  =  0.0001).  However,  no  signiﬁcant  difference  in  the
umber of  micronuclei  was  observed  between  the  negativeYCLE, cyclophosphamide  (positive  control);  1,  exposure  for  1
ay; 5,  exposure  for  5  days;  ©,  outlier;  *,  the  outlier  of  the
utlier; the  numbering  over  the  outlier  corresponds  to  the  num-
ering of  animals.
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Figure  2  Examples  of  a  polychromatic  erythrocyte  with  a
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uicronucleus (large  arrow)  and  a  normal  polychromatic  erythro-
yte (narrow  arrow);  the  animal  was  exposed  to  mepivacaine  for
 days  (Giemsa  staining,  1000×).
With  the  exception  of  the  cyclophosphamide  group,  all
roups were  equal  for  multiple  statistical  analyses.  However,
igniﬁcant differences  in  the  frequencies  of  micronuclei
ere observed  between  the  prilocaine  5-day  exposure  group
nd the  following  groups:  lidocaine  1-day  exposure  group
p = 0.0466),  the  mepivacaine  1-  (p  =  0.0437)  and  5-day
p = 0.0460)  exposure  groups  and  the  articaine  1-day  expo-
ure group  (p  =  0.0364)  (Table  1).
iscussionenotoxicity  tests  are  important  for  the  evaluation  of  cellu-
ar toxicity  and  the  identiﬁcation  of  potential  carcinogens
nd mutagens.  Several  techniques  are  employed  to  test
Table  1  Median  and  interquartile  ranges  of  the  frequency
of micronuclei  for  each  group  (n  =  80).
Group  Median  Interquartile  range
Lidocaine  --  1  day  1.00a  3.00
Lidocaine --  5  days  0.50a,c  2.00
Mepivacaine --  1  day 1.00a  1.00
Mepivacaine -- 5  days 1.00a 2.00
Articaine --  1  day 1.00a  2.00
Articaine --  5  days  0.00a,c  1.00
Prilocaine --  1  day  0.00a,c  1.00
Prilocaine --  5  days  0.00c  1.00
Negative control  --  1  day  1.00a,c  2.00
Negative control  --  5  days  0.00a,c  4.00
Cyclophosphamidea 10.00d  3.00
a Positive control. Results with different letters differ signiﬁ-
cantly  (p < 0.05).
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n  agent’s  genotoxic  activity,  including  assays  that  deter-
ine DNA/protein  cross-linking  coefﬁcients,  mitochondrial
nzymatic activity,  cell  proliferation,  repair  of  DNA  breaks,
itotic index,  the  type  of  damage  incurred,  chromosomal
berrations, chromosomal  non-disjunctions,  and  levels  of
poptosis and  necrosis.8 The  micronucleus  test  has  been
sed extensively  to  test  the  genotoxicity  of  many  chemi-
als. Micronuclei  are  easily  viewed  in  erythrocyte  samples
nd are  strongly  indicative  of  chromosomal  aberrations.6
The  micronucleus  test  was  ﬁrst  reported  in  1970  by
oller and  Schmid  and  was  subsequently  used  by  Heddle
n 1977.10 The  micronucleus  is  an  additional  nucleus,  sep-
rated from  the  main  nuclear  core  of  a  cell  during  cell
ivision and  comprises  whole  chromosomes  or  chromosomal
ragments that  lag  behind  the  other  chromosomes  upon  the
ompletion of  mitosis.  The  micronucleus  results  from  spon-
aneous  or  experimentally  induced  structural  changes  in  the
hromosome(s), or  through  cellular  fusion  errors,  and  it  is
herefore excluded  from  the  new  nucleus  that  is  re-formed
n telophase.11
The  advantages  of  the  micronucleus  assay  over  other
ests used  to  diagnose  diseases  and  monitor  environmen-
al contaminants  include  its  simplistic  analysis,  its  high
etection sensitivity  and  accuracy  of  chromosome  losses
nd nondisjunction  events,  its  ability  to  measure  the  length
nd progression  of  nuclear  division  and  its  ability  to  detect
epair and  excision  events.8 These  advantages  prompted  us
o choose  the  micronucleus  test  to  evaluate  the  genotoxic
ffects of  repetitive  administration  of  local  anaesthetics  in
his study.
A disadvantage  of  using  vasoconstrictors  in  conjunction
ith local  anaesthetics  is  apparent  with  intravascular  injec-
ions, during  which  high  concentrations  and  large  volumes
an lead  to  intoxication.12 Thus,  in  some  patients,  it  is  unac-
eptable to  use  vasoconstrictors,  particularly  in  those  with
iabetes or  heart  disease  or  pregnant  women.  In  these  cases,
he most  commonly  used  anaesthetic  salt  in  the  absence  of
 vasoconstrictor  is  mepivacaine.12 Thus,  mepivacaine  was
sed in  this  study  without  a  vasoconstrictor.  There  are  no
nown reports  in  the  literature  that  evaluate  the  genotoxic
ction of  vasoconstrictors.
Prilocaine was  previously  reported  to  exhibit  genotoxic
ctivity in  somatic  cells  and  to  be  capable  of  inducing
omologous recombination.  However,  lidocaine  and  arti-
aine (Septanest®)  were  reportedly  incapable  of  inducing
hromosomal mutation  or  recombination.13 No  genotoxicity
as associated  with  the  use  of  any  of  the  drugs  examined
n this  study.  These  results  are  in  partial  agreement  with
he literature,  and  differ  only  with  the  previous  report  of
rilocaine genotoxicity.13
It  has  been  demonstrated  that  the  percentage  of  cells
ith polyploidy  and  endoreduplication  increases  upon  expo-
ure to  prilocaine  hydrochloride  and  procaine  hydrochloride
oth in  the  presence  and  absence  of  exogenous  metabolic
ctivation.14 These  results  indicate  that  such  chemical
gents are  potentially  genotoxic  to  mammalian  cells.14 How-
ver, this  study  did  not  show  genotoxic  action  of  prilocaine,
ossibly because  it  was  used  at  the  recommended  dose  per
ilogram of  weight.
Nuclear condensation  and  fragmentation  of  chromatin
ere previously  observed  in  cells  treated  with  prilocaine.15
NA  fragmentation  was  also  induced  by  prilocaine
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treatment  in  a  dose-  and  time-dependent  manner,  with
maximal effects  observed  at  a  concentration  of  5  mM  after
12--48 h  of  exposure.15 Together  with  this  study,  these  data
show that  using  prilocaine  at  the  recommended  dose  per
kilogram of  body  weight  cannot  cause  genetic  damage.
Lidocaine  and  prilocaine  are  mainly  metabolised  in  the
liver and  subsequently  hydrolysed  by  amide  esters,  releasing
the monocyclic  aromatic  amines,  2,6-dimethylaniline  (DMA)
and 2-methylalanine  (MA),  respectively.5 Other  anaesthetics
that contain  a  fraction  of  DMA  include  bupivacaine,  mepiva-
caine and  ropivacaine.5
The  main  carcinogenic  mechanism  of  aromatic  amines
such as  DMA  and  MA  occurs  when  cytochrome  P450
metabolises these  compounds  into  derivatives  of  N-
hidroxila.5 DMA  and  MA  can  be  further  metabolised  by  their
conjugation to  reactive  metabolites.  The  DNA  lesion  has
been described  for  DMA,  but  not  for  MA.  The  formation
of DNA  adducts  is  thought  to  be  a  possible  mechanism  by
which these  compounds  exert  some  of  their  carcinogenic
effects.16
However,  the  International  Agency  for  Research  on  Can-
cer (IARC)  reported  no  carcinogenic  effects  of  DMA  in
humans, although  there  is  sufﬁcient  evidence  of  its  car-
cinogenicity in  rats.5 This  may  explain  the  greater  numbers
of micronuclei  observed  in  the  lidocaine  group  (regardless
of exposure  time)  compared  to  the  prilocaine  group  and
the signiﬁcant  difference  between  the  groups  exposed  to
lidocaine for  1  day  and  prilocaine  for  5  days  (p  =  0.0466).
Although the  frequency  of  micronuclei  in  the  lidocaine-
exposed group  was  not  signiﬁcantly  different  from  that
of the  negative  control  group,  the  higher  frequency  of
micronuclei in  the  lidocaine-exposed  group  (compared  to
the prilocaine  group)  may  be  associated  with  the  effects  of
DMA, a  metabolic  product  of  lidocaine.
There  are  no  literature  reports  regarding  the  genotoxic
or mutagenic  potential  of  mepivacaine.  In  this  study,  mepi-
vacaine exhibited  no  genotoxicity,  regardless  of  exposure
time. However,  exposure  of  mepivacaine  for  1  and  5  days  was
signiﬁcantly different  from  the  group  exposed  to  prilocaine
for 5  days  (p  <  0.05).  Mepivacaine  also  contains  a  fraction  of
DMA,5 which  may  explain  the  higher  number  of  micronuclei
observed in  this  group,  although  the  frequency  of  micronu-
clei was  not  signiﬁcantly  different  from  the  negative  control
group.
Mutagenicity studies  in  vitro  and  in  vivo  revealed  no
genotoxic potential  of  articaine  (CAS  23964-58-1)  until
the maximum  tolerated  dose  was  reached.  In  agreement
with the  data  in  this  study,  another  articaine  prepara-
tion (Septanest® SP;  4%  articaine  HCl  and  epinephrine  1:
100,000)17 exhibited  no  genotoxic  effects  in  an  in  vivo
study using  the  recommended  dose  per  kilogram  of  weight.
Although articaine  belongs  to  the  amide  group  of  local
anaesthetics (which  also  includes  lidocaine,  prilocaine  and
mepivacaine), it  is  metabolised  by  cholinesterase  in  serum
plasma into  articainic  acid  via  hydrolysis.  Articainic  acid
is an  inactive  metabolite  and  is  partially  metabolised  in
the kidney  into  articainic  acid  glucuronide,  rather  than  a
potentially genotoxic  aromatic  amine.18 This  result  may  par-
tially explain  the  absence  of  genotoxicity  upon  articaine
exposure. However,  the  1-day  articaine  exposure  group  was
signiﬁcantly different  from  the  5-day  prilocaine  exposure
group (p  =  0.0364).  This  may  be  due  to  the  presence  of  an
125
utlier  in  the  articaine  group,  which  was  well  above  the
verall median  frequency  of  micronuclei.
onclusion
n  the  present  study,  there  was  no  increased  frequency  of
icronuclei upon  exposure  to  any  of  the  local  anaesthet-
cs tested  (lidocaine,  mepivacaine,  articaine  and  prilocaine)
hen used  at  the  recommended  dose  per  kilogram  of  body
eight, with  either  a  single  exposure  or  upon  repetitive
dministration. However,  other  tests  that  assess  genotox-
city and  mutagenicity  should  be  applied  to  deﬁnitively
etermine that  the  repetitive  use  of  these  anaesthetics  has
o  genotoxic  or  mutagenic  activity.
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